Literature DB >> 9373249

Functional heterogeneity of human CD34(+) cells isolated in subcompartments of the G0 /G1 phase of the cell cycle.

A Gothot1, R Pyatt, J McMahel, S Rice, E F Srour.   

Abstract

Using simultaneous Hoechst 33342 (Hst) and Pyronin Y (PY) staining for determination of DNA and RNA content, respectively, human CD34(+) cells were isolated in subcompartments of the G0 /G1 phase of the cell cycle by flow cytometric cell sorting. In both bone marrow (BM) and mobilized peripheral blood (MPB) CD34(+) cells, primitive long-term hematopoietic culture-initiating cell (LTHC-IC) activity was higher in CD34(+) cells isolated in G0 (G0CD34(+) cells) than in those residing in G1 (G1CD34(+) cells). However, as MPB CD34(+) cells displayed a more homogeneous cell-cycle status within the G0 /G1 phase and a relative absence of cells in late G1 , DNA/RNA fractionation was less effective in segregating LTHC-IC in MPB than in BM. BM CD34(+) cells belonging to four subcompartments of increasing RNA content within the G0 /G1 phase were evaluated in functional assays. The persistence of CD34 expression in suspension culture was inversely correlated with the initial RNA content of test cells. Multipotential progenitors were present in G0 or early G1 subcompartments, while lineage-restricted granulomonocytic progenitors were more abundant in late G1 . In vitro hematopoiesis was maintained for up to 6 weeks with G0CD34(+) cells, whereas production of clonogenic progenitors was more limited in cultures initiated with G1CD34(+) cells. To test the hypothesis that primitive LTHC-ICs would reenter a state of relative quiescence after in vitro division, BM CD34(+) cells proliferating in ex vivo cultures were identified from their quiescent counterparts by a relative loss of membrane intercalating dye PKH2, and were further fractionated with Hst and PY. The same functional hierarchy was documented within the PKH2(dim) population whereby LTHC-IC frequency was higher for CD34(+) cells reselected in G0 after in vitro division than for CD34(+) cells reisolated in G1 or in S/G2 + M. However, the highest LTHC-IC frequency was found in quiescent PKH2(bright) CD34(+) cells. Together, these results support the concept that cells with distinct hematopoietic capabilities follow different pathways during the G0 /G1 phase of the cell cycle both in vivo and during ex vivo culture.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9373249

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  Identification and characterization of a resident vascular stem/progenitor cell population in preexisting blood vessels.

Authors:  Hisamichi Naito; Hiroyasu Kidoya; Susumu Sakimoto; Taku Wakabayashi; Nobuyuki Takakura
Journal:  EMBO J       Date:  2011-12-16       Impact factor: 11.598

2.  Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells.

Authors:  Raphael Ceccaldi; Kalindi Parmar; Enguerran Mouly; Marc Delord; Jung Min Kim; Marie Regairaz; Marika Pla; Nadia Vasquez; Qing-Shuo Zhang; Corinne Pondarre; Régis Peffault de Latour; Eliane Gluckman; Marina Cavazzana-Calvo; Thierry Leblanc; Jérôme Larghero; Markus Grompe; Gérard Socié; Alan D D'Andrea; Jean Soulier
Journal:  Cell Stem Cell       Date:  2012-06-07       Impact factor: 24.633

3.  HIF-1α deletion partially rescues defects of hematopoietic stem cell quiescence caused by Cited2 deficiency.

Authors:  Jinwei Du; Yu Chen; Qiang Li; Xiangzi Han; Cindy Cheng; Zhengqi Wang; David Danielpour; Sally L Dunwoodie; Kevin D Bunting; Yu-Chung Yang
Journal:  Blood       Date:  2012-02-02       Impact factor: 22.113

4.  Biophysical differences between chronic myelogenous leukemic quiescent and proliferating stem/progenitor cells.

Authors:  Nataliia V Guz; Sapan J Patel; Maxim E Dokukin; Bayard Clarkson; Igor Sokolov
Journal:  Nanomedicine       Date:  2016-07-16       Impact factor: 5.307

5.  The murine long-term multi-lineage renewal marrow stem cell is a cycling cell.

Authors:  L R Goldberg; M S Dooner; K W Johnson; E F Papa; M G Pereira; M Del Tatto; D M Adler; J M Aliotta; P J Quesenberry
Journal:  Leukemia       Date:  2013-08-30       Impact factor: 11.528

6.  A Quiescent Bcl11b High Stem Cell Population Is Required for Maintenance of the Mammary Gland.

Authors:  Shang Cai; Tomer Kalisky; Debashis Sahoo; Piero Dalerba; Weiguo Feng; Yuan Lin; Dalong Qian; Angela Kong; Jeffrey Yu; Flora Wang; Elizabeth Y Chen; Ferenc A Scheeren; Angera H Kuo; Shaheen S Sikandar; Shigeo Hisamori; Linda J van Weele; Diane Heiser; Sopheak Sim; Jessica Lam; Stephen Quake; Michael F Clarke
Journal:  Cell Stem Cell       Date:  2016-12-29       Impact factor: 24.633

7.  Hematopoietic stem/progenitor cells express functional mitochondrial energy-dependent cystic fibrosis transmembrane conductance regulator.

Authors:  Donatella Piro; Claudia Piccoli; Lorenzo Guerra; Francesca Sassone; Annamaria D'Aprile; Maria Favia; Stefano Castellani; Sante Di Gioia; Silvia Lepore; Maria Luisa Garavaglia; Teresa Trotta; Angela Bruna Maffione; Valeria Casavola; Giuliano Meyer; Nazzareno Capitanio; Massimo Conese
Journal:  Stem Cells Dev       Date:  2011-06-20       Impact factor: 3.272

8.  P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells.

Authors:  Byeong-Chel Lee; Tao Cheng; Gregor B Adams; Eyal C Attar; Nobuyuki Miura; Sean Bong Lee; Yoriko Saito; Ivona Olszak; David Dombkowski; Douglas P Olson; Julie Hancock; Peter S Choi; Daniel A Haber; Andrew D Luster; David T Scadden
Journal:  Genes Dev       Date:  2003-07-01       Impact factor: 11.361

9.  Cytosine methylation dysregulation in neonates following intrauterine growth restriction.

Authors:  Francine Einstein; Reid F Thompson; Tushar D Bhagat; Melissa J Fazzari; Amit Verma; Nir Barzilai; John M Greally
Journal:  PLoS One       Date:  2010-01-26       Impact factor: 3.240

10.  Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib.

Authors:  Jasmine Foo; Mark W Drummond; Bayard Clarkson; Tessa Holyoake; Franziska Michor
Journal:  PLoS Comput Biol       Date:  2009-09-11       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.